AYTU a well-written article: "First to inspire, the aggregate sum of the markets targeted by AYTU’s two therapeutics Natesto® and ZolpiMist™ are estimated to be worth a combined $3.6BN ($1.8BN each for TRT and sleep), and the unique advantages of AYTU’s products create a clear opportunity for the company to grab a huge portion of this market opportunity".
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.